ESMO 2018 | Striking a balance between quantity and quality of life in nmCRPC
Robert Jones, MD, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, describes the important role of the physician in considering whether or not to adopt a new therapy for a cancer patient, while considering their needs. Prof. Jones uses the example of prolonging the onset of metastasis, and limiting the detrimental effects to the quality of life of patients with non-metastatic castration resistant prostate cancer (nmCRPC), to demonstrate the importance of striking a balance between quantity of life and quality of life. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
Get great new content delivered to your inboxSign up